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Aim: This study was designed to evaluate the efficacy and toxicities of concomitant boost intensity-modulated
radiation therapy (IMRT) along with capecitabine and oxaliplatin, followed by a cycle of Xelox, in neoadjuvant
course for locally advanced rectal cancer.
Materials and methods: Patients with histologically confirmed, newly diagnosed, locally advanced rectal
adenocarcinoma (cT3-T4 and/or cN+) located within 12 cm of the anal verge were included in this study. Patients
received IMRT to the pelvis of 50 Gy and a concomitant boost of 5 Gy to the primary tumor in 25 fractions, and
concurrent with oxaliplatin (50 mg/m2 d1 weekly) and capecitabine (625 mg/m2 bid d1–5 weekly). One cycle of
Xelox (oxaliplatin 130 mg/m2 on d1 and capecitabine 1000 mg/m2 twice daily d1–14) was given two weeks after
the completion of chemoradiation, and radical surgery was scheduled eight weeks after chemoradiation. Tumor
response was evaluated by tumor regression grade (TRG) system and acute toxicities were evaluated by NCI-CTC
3.0 criteria. Survival curves were estimated using the Kaplan-Meier method and compared with Log-rank test.
Results: A total of 78 patients were included between March 2009 and May 2011 (median age 54 years; 62 male).
Seventy-six patients underwent surgical resection. Twenty-eight patients underwent sphincter-sparing lower anterior
resection and 18 patients (23.7%) were evaluated as pathological complete response (pCR). The incidences of grade
3 hematologic toxicity, diarrhea, and radiation dermatitis were 3.8%, 10.3%, and 17.9%, respectively. The three-year
LR (local recurrence), DFS (disease-free survival) and OS (overall survival) rates were 14.6%, 63.8% and 77.4%, respectively.
Initial clinical T stage and tumor regression were independent prognostic factors to DFS.
Conclusion: An intensified regimen of concomitant boost radiotherapy plus concurrent capecitabine and
oxaliplatin, followed by one cycle of Xelox, can be safely administered in patients with locally advanced rectal
cancer, and produces a high rate of pCR. A prognostic score model is helpful to distinguish different long-term
prognosis groups in early stage.
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Preoperative chemoradiotherapy (CRT) followed by total
mesorectal excision (TME) is the standard treatment for
patients with locally advanced rectal cancer (LARC). Some
significant benefits of neoadjuvant CRT, such as better
local control and sphincter preservation, have been shown
in patients with stage II/III rectal cancer [1-3].
To obtain a better tumor response, elevating treatment
dose has been considered a feasible method. EORTC22921
and FFCD9203 studies showed that preoperative radiother-
apy combined with fluorouracil (5-FU) can significantly
improve the treatment effect compared with radiotherapy
alone [3,4]. In a retrospective analysis of 3,157 patients en-
rolled in seven randomized Phase III trials and 45 Phase II
trials, the use of continuous infusion 5-FU, a second drug
based on 5-FU and a higher radiation dose was associated
with higher rates of pCR [5]. However, the next five ran-
domized phase III trials, ACCORD 12/0405-Prodige 2 [6],
STAR-01 [7], NSABP R-04 [8], CAO/ARO/AIO-04 [9] and
PETACC-6 [10], demonstrated conflicting results as to
whether oxaliplation increased the rate of pCR.
In our center, most patients receiving neoadjuvant CRT
were clinical T4 or N+, and might have more opportun-
ities to benefit from a high intensity treatment, whether
chemotherapy or radiotherapy [11-13]. To decrease the
additional toxicities from a high-dose treatment, especially
diarrhea, intensity modulated radiotherapy (IMRT) was
used to lessen radiation-associated toxicities by decreasing
the volume of high irradiation dose of surrounding normal
tissues [14-16]. IMRT allows higher radiation doses to be
focused on regions within the tumor while minimizing the
dose to surrounding normal critical structures. The data
from dosimetric studies of IMRT in rectal cancer are en-
couraging. Compared to conventional 2D or 3D radiation
therapy, IMRT showed similar target coverage with re-
duced dose to the small bowel, bladder, pelvic bone and
femoral heads [14,17,18]. By decreasing the dose delivered
to normal structures, IMRT may provide a potential for
increasing treatment dose to improve tumor response.
Therefore, we designed this study to examine the use
of IMRT, escalating the primary lesion’s dose to 55 Gy
together with the whole pelvis dose of 50 Gy in 25 frac-
tions, along with weekly capecitabine and oxaliplatin.
Two weeks after the end of chemoradiotherapy, a cycle
of Xelox (capecitabine and oxaliplatin) was prescribed
before surgery. The efficacy and toxicity of this modality
were evaluated to explore the feasibility of high-dose in-
tensity in preoperative treatment. This phase II study
was approved by our institutional review board.
Materials and methods
Eligibility criteria
Patients with histologically confirmed, newly diagnosed,
locally advanced rectal adenocarcinoma (cT3-T4 and/orcN+) located within 12 cm from the anal verge were
included in this study at the Fudan University Shanghai
Cancer Center. All patients were ≥ 18 years of age and
had a Karnofsky Performance Status score of ≥ 60, no
evidence of distant metastases, adequate bone mar-
row function (leukocyte count > 4,000/mL and platelet
count > 100,000/mL), and adequate renal and hepatic
function (creatinine clearance > 50 mL/min and biliru-
bin ≤ 2 mg/mL). Patients were excluded if they were
older than 75 years of age, had undergone previous
pelvic radiotherapy or previous chemotherapy, or had
previous or synchronous tumors other than nonmela-
noma skin cancer. Patients suffering of the following
medical conditions were also ineligible: ischemic heart
disease, inflammatory bowel disease, malabsorption syn-
drome, peripheral neuropathy, or psychological disorders.
Signed informed consent was obtained from all patients
before inclusion on this study. The institutional review
board of Fudan University approved the study.
Baseline evaluation
Pretreatment evaluation was performed within two weeks
before initiation of chemoradiation. The evaluation in-
cluded a complete history and physical examination,
including digital rectal examination, complete blood
count, hepatic and renal function tests, tumor marker
measurement, colonoscopy and biopsy, computed tom-
ography (CT) of the thorax and abdomen, magnetic
resonance imaging (MRI) of the pelvis, and, in selected
patients, endorectal ultrasound. All patients were clinically
staged with the AJCC 7th version manual.
Combined chemoradiotherapy
Intensity modulated radiation therapy (IMRT)
All patients were immobilized in the prone position using
a belly board and underwent a non-contrast-enhanced,
planning CT with 5-mm slices from the L3-L4 junction
to 2 cm below the perineum. The image data were
transferred to the PINNACLE planning system (Philips
Radiation Oncology Systems, Milpitas, CA). The definitions
of volumes were in accordance with the ICRU Report #83
[19]. The gross tumor volume (GTV) was defined as all
known gross disease determined from CT and MRI. The
clinical target volume 1 (CTV1) included the gross tumor
volume and the corresponding mesorectum plus 2 cm
cranio-caudally. The CTV2 included the CTV1 plus the
entire mesorectum, entire pre-sacral space, internal iliac
nodes and high-risk anatomical and nodal sub-sites, based
on the distance of the tumor from the anal margin [20].
Based on our institution set-up data, the planning target
volume (PTV) was defined as the CTV with 10-mm mar-
gins superiorly and inferiorly and 8-mm margins in all
other directions. Organs at risk (OARs) were contoured as
follows: 1) the small intestine was defined as all intestinal
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excluded); 2) femoral heads were contoured from the cra-
nial extremity to the level of the lower margin of ischial
tuberosities; and 3) the bladder was contoured entirely
with no distinction between the wall and its content [16].
The IMRT plans were generated using the inverse plan-
ning module of PINNACLE for a 6-MV liner accelerator,
with five to seven coplanar fields.
The planned doses to the PTV1 and PTV2 were 55 Gy
and 50 Gy, respectively, in 25 fractions, five times per
week (Monday through Friday) for five weeks. The D2%,
D50%, and D98% to PTV1 and PTV2 were set at
52.25 Gy and 55 Gy, 57.75 Gy and 47.5 Gy, and 50 Gy
and 52.5 Gy, respectively. The doses of the OARs were
set as low as possible and had to at least meet the fol-
lowing constraints: bladder, ≥ 45 Gy in 15% volume
and ≥ 40 Gy in 40% volume; femoral heads, ≥ 45 Gy in
25% volume and ≥ 40 Gy in 40% volume; and small
bowel, ≥ 45 Gy in 65 cc volume, ≥ 40 Gy in 100 cc volume,
and ≥ 35 Gy in 180 cc volume.
The positioning and isocenter of each patient were
verified on electronic portal imaging device (EPID) films
for the anterior and lateral gantry positions by visually
comparing the digitally reconstructed radiographs.Concurrent and neoadjuvant chemotherapy
Capecitabine combined with oxaliplatin was administered
concurrently with pelvic radiation. Capecitabine was given
at a dose of 625 mg/m2 twice daily from Monday to Friday
throughout the entire course of IMRT. Oxaliplatin at a
dose of 50 mg/m2 was administered weekly during the
five-week course of radiotherapy. Two weeks after concur-
rent chemoradiation, one cycle of Xelox (oxaliplatin
130 mg/m2 on d1 and capecitabine 1000 mg/m2 twice









Figure 1 The workflow of preoperative chemoradiotherapy in patientSurgery and histopathology
Surgery was scheduled eight weeks after the completion
of CRT. Total mesorectal excision (TME) was mandatory,
whereas the form of surgery (anterior resection or
abdominal-perineal resection) and whether a temporary
colostomy should be performed were decided by the sur-
geon. All lymph nodes were examined according to stand-
ard procedures. If the number of lymph nodes was less
than 12, two pathologists were needed to sign to ensure
the reliability of the detection result. The circumferential
rectal margin (CRM) was assessed according to the
method of Quirke et al. [2], and a margin of < 1 mm was
considered CRM-positive. All sections of the surgical
specimens were reviewed by two pathologists. The patho-
logic stage (ypTN) was recorded according to the Union
for International Cancer Control (UICC) TNM system.
Tumor regression grading (TRG) was evaluated according
to the criteria by Dworak et al. as follows [21]: Grade 0, no
regression; Grade 1, dominant tumor mass with obvious
fibrosis and/or vasculopathy; Grade 2, dominant fibrotic
changes with few tumor cells or groups (easy to find);
Grade 3, very few (difficult to find microscopically) tumor
cells in fibrotic tissue with or without mucous substance;
and Grade 4, no tumor cells, only a fibrotic mass (total
regression or response).Adjuvant chemotherapy and follow-up
All patients were recommended to receive postoperative
chemotherapy regardless of pathological stages. Ad-
juvant chemotherapy was recommended consisting of
five cycles of Xelox. Patient follow-up was scheduled
every three months during the first two years, and
then every six months over the next three years. After
five years, the frequency of follow-up was extended to
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Table 2 Toxicity during the course of chemoradiation
Grade 1 Grade 2 Grade 3
n % n % n %
Diarrhea 15 19.2% 11 14.1% 8 10.3%
Hematologic 13 16.7% 3 3.8% 3 3.8%
Fatigue 10 12.8% 5 6.4% 3 3.8%
Radiation dermatitis 20 25.6% 16 20.5% 14 17.9%
Neurosensory 3 3.8% 1 1.3% 0 0.0%
Hand-foot syndrome 0 0.0% 1 1.3% 0 0.0%
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Toxicities were evaluated and recorded weekly according
to the CTC 3.0 criteria. If grade 3 toxicities occurred,
the physicians determined causes and decided the response.
In general, the sequence of dose reduction or suspension
moved from oxaliplatin to capecitabine to radiotherapy,
unless an adverse effect was strongly associated with a
particular treatment.
Endpoints and statistics
The primary endpoint for this trial was pCR rate. This
study was a phase II trial of 78 patients to evaluate the
treatment feasibility and efficacy of this dosing regimen.
Based on a literature review, the pCR rate is approxi-
mately 10–15% for patients treated with neoadjuvant
CRT. We determined that an experimental arm with a
pCR rate of at least 18% would merit further study. In
this study, if more than 17 cases were evaluated as pCR,
we had 85% power to reject the null hypothesis that our
strategy could not reach the pCR of 18%, with a type I
error level of 5%. Secondary endpoints included safety,
sphincter preservation rate, TRG, LR (local recurrence),
DFS (disease-free survival) and OS (overall survival).
Sphincter preservation was defined as any procedure
in which the rectal tumor was removed while leaving
behind the anal sphincter.
All characteristics were described by the frequency for
classified variables, by mean and standard deviations for
normal distributional continuous data, and by the me-
dian for non-normal distributional continuous data.
Survival time was calculated from the beginning of
CRT to the date of event or the last follow-up. Survival
curves were estimated using the Kaplan-Meier method
and compared with Log-rank test. Cox proportional haz-
ards regression was used for multivariate modeling and
for examining the prognostic significance of the variables
identified in the models. P values of less than 0.05 were
taken to indicate statistically significant differences.
Results
Clinical characteristics
Between March 2009 and May 2011, a total of 78 patients
were included in the study. All patients were diagnosed
with locally advanced rectal cancer: 50 with cT3 and 28
with cT4 primary tumor. Lymph node involvements were
detected in 75 patients. Of the total 78 patients, 62 were
men and 16 were women; the median age was 54 years
(range, 30–76 years). Fifty-six patients (71.8%) had tumors
located ≤ 5 cm from the anal verge (Table 1).
Treatment compliance and acute toxicities
All patients completed the prescribed radiation treatment
to a total dose of 55 Gy in 25 fractions. The median total
radiation duration was 37 days (range, 33–41). All patientscompleted five weeks of capecitabine, and 48 cases received
five cycles oxaliplatin and the rest received four cycles. In
addition, all patients received a scheduled single cycle of
Xelox two weeks after the completion of chemoradiother-
apy without dose adjustment.
Most of the adverse events during CRT were mild
(grade 1 or 2). No grade 4–5 toxicities were observed. The
most common grade 3 toxicity was radiation dermatitis
(17.9%), while grade 3 diarrhea and hematological toxic-
ities were evaluated in eight (10.3%) and three cases (3.8%)
(Table 2).
Surgical procedures and pathological response
Seventy-six patients underwent a surgical resection accord-
ing to the schedule. One patient refused surgery because of
good response, and another case did not receive an oper-
ation because of being evaluated as unresectable lesions.
The median interval between the completion of CRT and
primary tumor surgery was 52 days (range, 46–67 days).
Twenty-eight patients (36.8%) underwent sphincter-sparing
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in Table 3. ypT0 and ypN0 were found in 18 (23.7%) and
47 (61.8%) patients, respectively, with 18 patients (23.7%)
showing pCR. TRG information was available in pathologic
examination for all 76 patients receiving surgery. The TRG
stage was Grade 4 (pCR) in 18 patients, Grade 3 in 34 pa-
tients, Grade 2 in 17 patients, and Grade 1 in 7 patients. All
cases were divided into two subgroups: good responders
(defined as TRG 3–4) or poor responders (defined as TRG
1–2). More than or equal to 12 lymph nodes were found in
half of the patients. Lymphatic/vascular invasion and neural
invasion were confirmed in five and eight cases, respectively
(Table 3). The overall rate of postoperative complicationsTable 3 Surgical procedure and pathological findings
n %
Surgery
Anterior resection 28 36.8%
Abdominal perineal resection 46 60.5%
Hartmann 2 2.6%



























CRM: circumferential resection margin.
TRG: tumor regression grade.was 17.1%. Delayed sacral-wound healing, postoperative
bleeding and anastomotic leakage occurred in 9, 3 and 1
patients, respectively.
Follow-up
With a median follow-up of 30 months (range, 9–
48 months), 10 patients were diagnosed with local re-
currence and 19 patients were confirmed with distant
metastases (5 in the liver, 13 in the lung, and 1 in
bone). Fourteen patients died of rectal cancer. For the
two patients that did not receive surgery, one patient
was confirmed of tumor failure at 27 months and died
28 months after the beginning of CRT, and the other
patient did not present any evidence of failure at the
last visit of 9 months. The 3-year LR, DFS and OS rates
were 14.6%, 63.8% and 77.4%, respectively (Figure 2).
Univariate and multivariate analysis for LR and DFS
All potential prognostic factors, including age, gender,
distance from anal verge, cT stage, cN stage, ypT stage,
ypN stage and TRG score were evaluated using the
Kaplan-Meier method (compared with Log-rank test).
cT stage and pCR status demonstrated a correlation with
LR (Figure 3). No LR was observed in pCR cases. In the
next multivariate Cox regression analysis, only cT stage
was left in the model.
cT stage, ypT stage and TRG score exhibit a correl-
ation with DFS. YpT stage was excluded in the further
multivariate Cox regression analysis. Hazard ratios of
these two factors (cT stage and TRG score) were very
close to one another (Table 4). A prognostic scoring sys-
tem was produced, with each of the two unfavorable
prognostic factors allocated one point, including cT4
stage and poor responder. Use of the scoring system ledFigure 2 Survival curves of local recurrence, overall survival
(OS) and disease-free survival (DFS).
Figure 3 Local recurrence rates by clinical T stage (panels a) and pCR or not (panels b). pCR: pathological complete response.
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of 0), intermediate risk (score of 1), and high risk (score
of 2). The three-year DFS rates were significantly different
among the groups: the low-risk group, 81.1%; intermedi-
ate-risk group, 60.0%; and the high-risk group, 28.6%
(P = 0.000, Figure 4).
Discussion
Our study findings demonstrated that the IMRT tech-
nique, which decreases radiation-induced toxicities by a
lower high-dose irradiation volume, and an intensified
preoperative CRT followed by a cycle of Xelox resulted
in a pCR rate of 24.7%. These results are higher than
those of studies on preoperative conventional CRT con-
current with oxaliplatin (15–20%) [6-10]. Regarding tox-
icities, however, the high rate of pCR did not translate
into high local control compared to other trials. This
may be attributed to two factors, First, our study had a
small sample size, and therefore some certain remains.
Second, the percentage of cT4 and cN + tumors in our
study was significantly higher than some other trials
(cT4: 35.9% vs. 5-15%, cN+: 96.2% vs. 40-70%, respect-
ively) [1,3,5,7-11]. Our study found that the incidence of
grade 3 diarrhea, hematologic toxicity, and radiation
dermatitis was 10.3%, 3.8%, and 17.9%, respectively.
Consistent with our previous study [22], the incidences
of diarrhea and hematologic toxicity were slightly lowerTable 4 The values of β, hazard ratio and P values in Cox
multivariate regression model disease-free survival
β Hazard ratio P value
LR Clinical T stage (3 vs. 4) 1.23 3.43 0.05
DFS TRG score (3/4 vs. 1/2) 1.36 3.90 0.00
Clinical T stage (3 vs. 4) 1.11 3.04 0.01
LR: local recurrence.
DFS: disease-free survival.
TRG: tumor regression grade.compared with other reported stage III clinical trials. A
significant increase in the incidence of radiation dermatitis
was observed in our study, which might be attributed to a
lower irradiation field due to a distal rectal tumor location
in most cases. Finally, with a median follow-up of 30
months, our data showed that the baseline T stage and
treatment response were associated with long-term prog-
nosis. Patients with cT4 stage had a higher chance of
LR and distance metastases, but no LR was observed in
pCR cases, regardless of initial T stage. In addition, base-
line T stage and tumor response had equal effects to
predict DFS. Patients with cT3 and good response had
a three-year DFS of 81.1%, but for those with cT4 and
poor response, the three-year DFS declined to 28.6%.
The IMRT technique has been used widely in some
solid tumors. In our study, IMRT was used to concomi-
tantly boost the total irradiation dose to 55 Gy for the
gross tumor. The rationale was based on several dosi-
metric studies that showed that IMRT could significantly
decrease the surrounding organs’ high-dose irradiation
volume, especially the small bowel, compared with conven-
tional radiotherapy or 3DCRT [14,15]. Therefore, IMRT
provided the potential of elevating the dose to improve
the tumor response. This is consistent with results
from Hartley’s meta-analysis, which included a total of
3157 rectal cancer patients [5]. Our previous study of
stage IV rectal cancer demonstrated the feasibility to
deliver 45 Gy to the pelvis and a concomitant 10 Gy
boost to the gross tumor using IMRT [23].
Oxaliplatin is an effective drug for colorectal cancer
when combined with 5-FU. However, the results of five
recent large sample phase III trials are unclear as to
whether oxaliplatin is an appropriate radiation sensitizer.
Three studies, including NSABP R-04 [8], STAR-01 [7]
and PETACC-6 [10], all reported that additional oxali-
plation based on conventional CRT failed to increase
pCR rate and caused more toxicities, especially diarrhea.
Figure 4 Disease-free survival rates by clinical T stage (panels a), ypT stage (panels b), tumor regression (panels c) and prognostic
score (panels d). TRG: tumor regression grade.
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higher toxicity rate in the oxaliplatin group, together
with a significantly higher pCR rate [6]. The CAO/ARO/
AIO-04 trial was the only phase III trial supporting add-
itional oxaliplatin in preoperative CRT, which showed a
better tumor regression in the oxaliplatin group with-
out any additional toxicities [9]. However, our study
demonstrated an encouraging pCR and tumor shrinkage,
without high incidence of toxicities. This also illustrated
that IMRT was an effective method to offset toxicities
induced by high-dose CRT.
In several previous studies, early surrogate indicator
was focused to help to decide the strategy of adjuvant
therapy. Tumor regression after CRT, especially pCR, was
regarded as an important prognostic factor. The EORTC
22921 trial showed that patients with good response had a
significantly good prognosis compared with those with
poor response [24]. Capirci’s retrospective study of 566
patients with pCR also demonstrated an encouraging
prognosis [25]. In a retrospective study by MD Anderson
Cancer Center, tumor response was associated with the
five-year recurrence free survival, distant-metastasis rate
and LR [26]. Thus, after neoadjuvant therapy, conventional
adjuvant chemotherapy (oxaliplatin plus fluorouracil) might
be over-treatment to patients with good prognosis, but nouse to poor responders. Based on our data, a prognostic
score model including initial clinical T stage and tumor
response might be helpful to determine the adjuvant
chemotherapy regimen.
Conclusion
An intensified regimen of concomitant boost radiotherapy
plus concurrent capecitabine and oxaliplatin, followed by
one cycle of Xelox, can be safely administered in patients
with locally advanced rectal cancer, and produces a high
rate of pCR. A prognostic score model is helpful to distin-
guish different long-term prognosis groups in early stage.
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